REQUEST FOR QUALIFICATIONS (RFQ) & EXPRESSIONS OF INTEREST ...
From Expressions of Interest to a Workprogramme for 2003
description
Transcript of From Expressions of Interest to a Workprogramme for 2003
Slide 1
From Expressions of Interest to a Workprogramme for 2003
PRIORITY 1
Life sciences, genomics and biotechnology for health
Slide 2
FP6 - Expressions of Interest - Response
Priority theme 1:
Life Sciences, Genomics & Biotechnology for Health
IPs NoEs Unspecified Total
Fundamental genomics 288 190 45 523
Applied genomics & biotech 240 125 36 401
Major diseases 459 219 24 702
Cancer 196 102 4 302
Poverty related diseases 41 28 - 69
Total 1224 664 109 1997
17% of EoIs for all 7 priority themes
Slide 3
FP6 - Expressions of Interest - Theme 1
Distribution of EOIs - by type of submitting institution
65%
25%
4%6%
HigherEducation
ResearchInstitute
Industry
Other
Slide 4
FP6 - Expressions of Interest - Theme 1
Industry, including SME, involvement (% submitters)4% overall8% Fundamental knowledge and basic tools10% Applications of knowledge and technologies...
N.B 15% of budget for SMEs
Gender balance (% submitters)16% female84% male
Slide 5
EoIs- countries of submitters - Theme 1
No. of EoIs per country of submitter (n)
0
50
100
150
200
250
300
350
ATBE
BG CH CY CZDE DK EE ES FI
FR GR HU IE IL IS IT LT MT NL
NO PL PTRO SE Sl
SK UKOth
er
No. of EoIs
10 % from candidate countries
Slide 6
FP6 - Expressions of Interest - Theme 1
Outcome of the panel meeting
Categories of scientific topics - all panels
1. Strategic importance for Europe & thematic priority; ready for implementation through an IP or NoE
2. Not-relevant to the thematic priority; less obvious strategic importance for Europe
Some panels
3. Strategic importance for Europe & thematic priority; BUT not yet mature for an IP or NoE (based on the EoIs received)
4. Strategic importance but not covered by any EoIs or the EoIs were not well argued
Slide 7
FP6 - Expressions of Interest - Theme 1
Analysis Methodology
At the panel meeting in Bussels
“Citation list” of EoIs to start the discussion
- cited EoIs- non-cited EoIs- expert rapporteur for every EoI
Some EoIs analysed by more than one panel (broad scope)
Definition of topics for IP and NoE- no pre-selection of particular EoI or consortium
Slide 8
Fundamental knowledge and basic tools for functional genomics in all organisms
• In total, 30 recommended topics
• 15 topics will be published in first call; 15 in second call
• The selected topics will be open only for the call
indicated
• It is envisaged that no more than 1 project utilising a
new instrument will be funded for each topic
• There will be competition between topics as well as
within topic areas
• This will result in some topic areas not being supported
Slide 9
Gene expression and Proteomics
Examples
Structural genomics
Examples
• Advanced array technologies
• High throughput proteomics for large data set of protein-protein interactions
• In situ gene expression analysis in mouse and human tissues
• Membrane proteins • Supramolecular analysis (NoE) • Hardware and software for
automated technologies at synchrotron sites (IP)
• Viral replication• Large protein complexes
Slide 10
Comparative genomics & Population genetics
Examples
Bioinformatics
Examples
• Non-mammalian vertebrate models (IP)
• In-vivo imaging for phenotyping and functional analysis
• RNA interference screening in Arabidopsis for processes relevant to health
• Phenotyping human populations • Bacterial diversity with relevance to
human health (NoE)• High throughput genotyping in
human populations (NoE)
• Annotation of human and other genomes (NoE)
• Genomics grid for European research (NoE)
• Software platform to tackle sequence-structure-function relationships
Slide 11
Basic biological processes
Examples:
• Cell cycle
• Non-human embryonic stem
cell differentiation
• Erythroid development (IP)
• Lymphangiogenesis
• Inflammation processes (NoE)
• Ubiquitin-proteasome (NoE)
• Epigenetics (NoE)
• Kidney disease
• Peroxisomes
• Inner ear or retina
development
• DNA damage and repair
• Disease of the immune
system or of the muscle
• X-linked syndromes
Slide 12
Traditional instruments
Examples:
• Transcription activation
• Signal transduction
• Intracellular communication
• Non-coding genomic information
• Integration of genes
• In silico prediction of gene function
• Simulation of complex regulatory networks
• New tools and approaches, standard protocols producing
knowledge in functional and structural genomics
Slide 13
Applications of knowledge and technologies in the field of genomics and biotechnology for health
Strategic Objective:
To foster the competitiveness of Europe’s biotechnology industry by exploiting the wealth of biological data produced by genomics and advances in biotechnology
Slide 14
Applications of knowledge and technologies in the field of genomics and biotechnology for health
Development of Technological Platforms
TECHNOLOGICAL PLATFORMS
IntegratedMultidisciplinaryResearch
EU project
- Health care progress- Increased quality of life- Cost reduction- Precise diagnostics- Individualised treatments- New drugs and therapies- Novel products from genomicsand biotechnology
Deliverables
• Industry• SME• Academics• Stakeholders
Civil society
Slide 15
Applications of knowledge and technologies in the field of genomics and biotechnology for health
Technology Platforms will focus their research activities on:
• New, safer and more effective drugs including pharmacogenomics approaches
• New diagnostics
• New in vitro tests to replace animal experimentation
• New preventive and therapeutic tools such as somatic gene and cell therapies (in particular stem cell therapies) and immunotherapies
• Innovative research in post-genomics (novel products from genomics and biotechnology)
Slide 16
STEM CELL Therapies
• Detailed implementing provisions concerning research
activities involving the use of human embryos and
human embryonic stem cells which may be funded
under the 6th Framework Programme shall be
established by 31 December 2003.
• During that period and pending establishment of the
detailed implementing provision, the Commission will
not propose to fund such research, with the exception
of the study of banked or isolated human embryonic
stem cells in culture.
Slide 17
New, safer and more effective drugs including pharmacogenomics approaches
Examples
Development of new diagnosticsExamples
Development of new in vitro testsExamples
• Drugs for aberrant molecular signalling in protein phosphorylation pathways (IP)
• Genome-based individualised medicine
• Drugs for psychiatric disorders (NoE)• Antiviral therapies (IP)
• Medicines for paediatrics
• Computer-assisted modelling for drugs
• Therapeutics for neurodegenerative diseases
• Genetic tests allowing for harmonisation, validation and standardisation
• In-vivo molecular imaging
• Non-invasive diagnostics: Development of markets for ante- and neonatal screening (NoE)
• Test batteries for human acute toxicity
• Combined in vitro cell and sensor technologies for animal toxicology (IP)
Slide 18
New preventive and therapeutic toolsExamples
Innovative research in Post-Genomics
Examples
• New cell lines for cell-based therapies (IP)
• Allogenic stem cell transplantation for haematological and neoplastic diseases (IP)
• Cell-based therapies for regeneration of connective tissue (IP)
• Gene delivery systems against severe acquired diseases
• Gene therapy of inherited diseases
• Safety, quality, standardisation of stem cells (European registry)
• Regeneration therapies for vital organs
• Vaccine delivery systems (bacterial, synthetic, aimed at dendritic cells, etc…)
• New chemokine modulators in autoimmune diseases
• Post-genomic approaches against asthma and autoimmune diseases (IP)
• Plant platforms for immunotherapeutic biomolecule production (IP)
• RNA as human therapeutic tool • Post-genomic approaches to study
human pathogens • Pre-clinical and clinical applications
Slide 19
New, safer and more effective drugs including pharmacogenomics approaches
Examples: Blood substitutes (e.g. oxygen carriers), G-Protein coupled receptors
Development of new diagnostics
Development of new in vitro tests
Examples: Non-invasive diagnostics using bioinformatics tools, Diagnostics for prion diseases
Examples: Competitive product screening & development process stages lead compounds by introduction of alternative testing
New preventive and therapeutic toolsExamples: Vaccine technologies targeted to dendritic cells
Databank on immuno therapies, comprising advances fromgenomics, proteomics and cell biologyStem cell products for myocardial repair
Innovative research in post-genomicsExamples: Combinatorial biosynthesis, Optically-active therapeutic
biomolecules by biocatalysis, Precision technology platforms from post-genomics
Slide 20
Combating major diseases
Fields of research:
• Combating cardiovascular diseases, diabetes and rare diseases
• Combating resistance to antibiotics and other drugs
• Studying the brain and combating diseases of the nervous system
• Studying human development and the ageing process
TOTAL
• Cancer
286
77
281
58
Number of EoIs:
702
58
Slide 21
Combating cardiovascular disease, diabetes and rare diseases
Examples:
• Molecular targets in obesity from diabetes
• Coronary Artery Disease• Genomics of heart muscle
development (NoE)• Genomics of vascular disease
(NoE)• Pancreatic ion channels in type II
diabetes (IP) • Rare disorders of mitochondria
• Hypertension• Genomics of type II
diabetes• Exercise and
metabolic syndrome• Eicosanoids and
nitric oxide as mediators of diseases
• Rare disorders of plasma membrane transporters
N° of EoIs: 286
Slide 22
Combating resistance to antibiotics and other drugs
Examples:
• Upper Respiratory Tract Infections (NoE)
• Anti-viral drug resistance
• Antibiotics producing organisms
• New targets for drugs - the ribosome
• Anti-fungal resistance• Microbial ecology -
epidemiology• Control of hospital acquired
infections
• Broadening the knowledge base on molecular mechanisms behind resistance
• Non antimicrobial therapies
Slide 23
Studying the brain and combating diseases of the nervous system
Examples:
• Protein aggregation
• Eating disorders (IP)• Bipolar disorders (IP)• Rare neurological diseases:
ataxias• Brain development,
degeneration and regeneration (NoE)
• Brain tissue research (NoE)
• Addiction• Cortical processing:
learning, memory, behavior
• Cortical development• Stem cells and
nervous system
• Rare monogenic neurological disorders, Genetics and neurobiology of pain, Schizophrenia
N° of EoIs: 281
Slide 24
Human Development and Ageing
Examples:
• Longevity
• Mesodermal organ system (NoE)
• Mitochondrial dysfunction
• Embryo implantation• Congenital anomalies
Markers• Aberrant Steroid
signalling
• Biochemistry of Reactive Oxygen Species• Molecular mechanisms of bone homeostasis
N° of EoIs: 58
Slide 25
Cancer
Selected 6 out of 14 topics for first call in order to ensure:
Potential co-ordination of complementary areas (e.g. molecular targets - molecular imaging)
Balanced coverage of the main WP areas:
A. Establishing facilities for exploitation of research• Registries and repositories
B. Clinical research • European networks for clinical trials• Molecular imaging for early detection • Radiation therapy
C. Translational research• Functional oncogenomics• Molecular targets
Slide 26
Overall Research Strategy of the 6th Framework Programme to confront HIV/AIDS, Malaria and Tuberculosis
EUROPEAN DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP)
• Vaccines
• Microbicides
• Therapy Trials in Europe
• Vaccines
• Biology and
Pathology (NoE)
• Drugs
•Vaccines
•Drugs
HIV/AIDS Malaria TB
NEW INSTRUMENTS
H I G H R I S K P R O J E C T S ( S T R E P)
CROSS-CUTTING TOPICS: Mucosal vaccines for PRD
Neonatal vaccination strategies for PRD
Pre-clinical
Discovery
Genomics
Clinical Trials(Phase II/III)
Phase I trials
Slide 27
Confronting the major communicable diseases linked to poverty
Fields of research Number of EoIsTuberculosis 13Malaria 17HIV 22Horizontal topics coveringthe three diseases
11
Not relevant1 6TOTAL 69
High level of interest, excellent quality of the EoI: most EU leading researchers represented in one or more EoI
Slide 28
EoI’s Panel main recommendations
• Encourage participation of partners from DC
• Stimulate the training component both for the North
and the South
• Increase the professionalism of management
• Include in the projects pre-clinical testing in non-
human primates and GMP production of candidate
drugs or vaccines
Slide 29
From Expressions of Interest to a Workprogramme for 2003
PRIORITY 5
Food Quality & Safety
Slide 30
Response to invitation to submit Expressions of Interest for priority 5
Type of instrument Type of submitter
Gender of submitter
eoi
Not indicated
Integrated project
Network of excellence
24%
33%43%
EOI
industrial
public
educational
51%
41%8%
MALE
FEMALE
77%
23%
Slide 31
Expert comments on nonselected EoI
• Very many EOIs on similar subjects
• Many were technical skills looking for funds
• Many were on a very large scale with little indication of
management skills
• Need for a “Development Bank” business plan approach
• Lack of analysis on the importance of the problems to be
addressed and of any potential benefits
• No gender balance awareness
• IP management was weak
• No gender balance awareness and IP management was weak
Slide 32
From EoI to Workprogramme
• Budget: 149 M€ in 2003
• Focussing: from 53 topics through EoIs down to ...
• Consultation of AG and committee
• Maturity of the topic
• Readiness of the topics for new instruments or
traditional instruments
• Urgency of the issue: 2003 or 2004
Slide 33
Format of the Draft Workprogramme (1)
• Common format for all Thematic Priorities
• Follows the specific programme
• Introduction to each area: clear signals
• NI (NE/ IP) or TI (STREP/ CA)
Slide 34
Format of the Draft Workprogramme (2)
• 2003:- selected topics
- detailed description
(objectives/disciplines/expected outcome)
• 2004:- indicative areas
- outline description
• Objectives for Specific Support Measures
Slide 35
A likely (but non-binding) scenario
2003 2004Area NI TI NI TITotal food chain 2 1 1 0Epidemiology of food-related diseases andallergies
1 1 2 1
Impact of food on health 2 1 4 0Traceability processes along the food chain 1 0 0 0Methods of analysis, detection and control 2 1 2 1Safer and environmentally production methods 3 4 3 5Impact of animal feed on human health 1 1 0 0Environmental health risk 2 2 2 2Total 14 11 14 9
Slide 36
Total Food Chain
Examples:
Food from low input and organic production systems: Ensuring the safety and improving quality along the whole chain
Quality seafood for improved consumer health and well-being
Improving the quality and safety of beef for the consumer
Pathogen free production systems
Slide 37
Epidemiology of food-related diseases and allergies
Examples:
Validated food information database for Europe (NoE) Epidemiology of food allergy Influence of gene-nutrient interaction on the development of
chronic diseases
Influence of nutrition and lifestyle on healthy ageing aimed at preventing adult degenerative disease
Nutritional and lifestyle habits of adolescents throughout Europe, including production of functional foods with sensory properties attractive to adolescents
Slide 38
Impact of food on health
Examples:
Functional genomics in relation to food, nutrition and health (NoE)
Lipid metabolism and the metabolic syndrome Food safety, risk assessment and communication Programming effects of early nutrition on long-term health Microbes, the immune system and gut health Improving and enhancing the nutritional value and health
benefits of cereals
Health risks from heat-treated foods and food products
Slide 39
“Traceability” processes along the production chain
Development of reliable traceability methods and systems to establish the origin/mode of productin of food products
Slide 40
Methods of analysis, detection and control
Examples:
Zoonoses including food borne diseases (NoE) Prion diseases (NoE) Chemical contaminants in food products Emerging and future food borne pathogenic microorganisms
throughout the food chain
Quantitative risk assessment strategies based on probabilistic, genomic and profiling approaches including a risk-benefit analysis for novel foods
Cost-effective tools for risk management and traceability systems for zoonotic agents and phycotoxins in seafood
Slide 41
Safer and environmentally friendly production methods and healthier foodstuffs
High throughput analysis of plant composition and metabolism for optimising end-product quality
Animal welfare for improved food quality
Genomics of host-pathogen interactions in animals (NoE)
Soil microbial community management for safe production under stress conditions
Plant biodiversity to reduce pesticide application
Immunological basis for protection against animal disease
Antibiotic resistance Crop protection systems based on biological control agents and semiochemicals Modelling of improved crop establishment in low input systems Plant flavonoids Recycled organic wastes from the food chain Sustainable aquaculture GMO co-existence analysis Use of genetic resistance to control plant viruses Disease risk from alternative and enriched cage and free-range systems
Examples:
Slide 42
Impact of animal feed on human health
New strategies to improve grain legumes for food and feed
Alternatives to antimicrobials in feeds
Slide 43
Environmental health risks
Examples:
Allergy and asthma network Exposure to chemical residues in the environment Environmental factors and puberty onset Cancer risk from environment, diet and genetic
Human pathogens in drinking water Food and fertility Neurotoxic effects of environmental contamineants Exposure to complex chemical mixtures